$0.80
0.00% yesterday
Nasdaq, Feb 04, 09:11 pm CET
ISIN
US2697961082
Symbol
EGRX
Sector
Industry

Eagle Pharmaceuticals, Inc. Stock price

$0.80
+0.28 52.38% 1M
-3.56 81.65% 6M
+0.30 60.00% YTD
-4.80 85.71% 1Y
-43.78 98.21% 3Y
-54.70 98.56% 5Y
-18.09 95.77% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.00 0.00%
ISIN
US2697961082
Symbol
EGRX
Sector
Industry

Key metrics

Market capitalization $10.39m
Enterprise Value $67.49m
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.26
P/S ratio (TTM) P/S ratio 0.04
Short interest 4.19%

Is Eagle Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Eagle Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:

1x Buy
50%
1x Sell
50%

Analyst Opinions

2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:

Buy
50%
Sell
50%

Financial data from Eagle Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '22
+/-
%
317 317
85% 85%
100%
- Direct Costs 96 96
127% 127%
30%
221 221
71% 71%
70%
- Selling and Administrative Expenses 80 80
14% 14%
25%
- Research and Development Expense 34 34
34% 34%
11%
107 107
1,309% 1,309%
34%
- Depreciation and Amortization 13 13
176% 176%
4%
EBIT (Operating Income) EBIT 94 94
3,278% 3,278%
30%
Net Profit 36 36
513% 513%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Eagle Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eagle Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
3 months ago
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has notified The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the “SEC”) to complete the previously-disclosed process t...
Neutral
Accesswire
4 months ago
WILMINGTON, DE / ACCESSWIRE / October 22, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ GM:EGRX) on behalf of stockholders.
Positive
GuruFocus
4 months ago
On October 3, 2024, Union Square Park Capital Management, LLC (Trades, Portfolio) made a significant move in the pharmaceutical sector by acquiring 1,191,490 shares of Eagle Pharmaceuticals Inc (EGRX, Financial). This transaction marked a new holding for the firm, purchased at a price of $1.99 per share.
More Eagle Pharmaceuticals, Inc. News

Company Profile

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Head office United States
CEO Michael Graves
Founded 2007
Website www.eagleus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today